Kwangathi i-2022: I-FDA igunyaza ukusetshenziswa kwesilingo somtholampilo sokwelashwa okuqondile kwe-CAR-NK FT536 ekwelapheni izimila eziqinile ovivinyweni lomtholampilo lwe-CAR-NK. I-FDA igunyaze Isicelo Sezidakamizwa Esisha Esiphenyayo ngoJanuwari 2022 sokwelashwa kwe-CAR-NK i-FT536 ukuze selaphe abantu abanezifo ezimbi ezibuyele emuva noma ezingazweli. Kulolu cwaningo, iziguli ezinomdlavuza wamaphaphu ongewona omncane omncane, umdlavuza we-colorectal, umdlavuza wekhanda nentamo, umdlavuza wesisu, umdlavuza webele, umdlavuza we-ovarian, nomdlavuza we-pancreatic zizothola i-FT536 njenge-monotherapy noma ihlanganiswe ne-monoclonal antibody. I-FT536 (I-Fate Therapeutics) iyi-allogeneic, i-multiple-engineered natural killer cell treatment (NK) ekhiqizwa kusukela kumaseli esiqu e-pluripotent.
Lokhu ukwelashwa kweseli ye-NK eyenziwe ngofuzo eveza i-CAR eqondise izizinda ze-alpha-3 ze-MICA ne-MICB, amaprotheni amabili abandakanyeka esigabeni esikhulu se-histocompatibility complex complex I. Womabili angamaprotheni okucindezeleka akhiqizwa kakhulu kumathumba amaningi aqinile futhi anganqoba. ukuchithwa ukuze kubuyiselwe ukungatheleleki kwe-tumor okuqondiswa yi-NK kanye nama-T cell. Sekukonke, i-FT536 iqukethe izinguquko ezine zokusebenza: i-CAR yobunikazi eqondise i-MICA kanye nesizinda se-MICB esi-3; inoveli ephezulu ehambisana ne-158V, i-CD16 engasuki (hnCD16) Fc receptor ethuthukisa i-ADCC; ithuthukisa amaseli e-NK athuthukisiwe Asebenzayo i-IL-15 receptor fusion (IL-15RF); kanye nokuhoxiswa kwesisho se-CD38, ngaleyo ndlela kuthuthukisa ukuqina komzimba we-NK cell, ukuphikelela, nokusebenza kwe-antitumor.
We expect that FT536 therapy can obtain positive data as soon as possible in clinical trials of solid izicubu, and it will be launched as soon as possible to benefit patients.
